Assessing the Financial Benefits of Faster Development Times: The Case of Single-source Versus Multi-vendor Outsourced Biopharmaceutical Manufacturing.

DiMasi, Joseph A; Smith, Zachary; Getz, Kenneth A

DiMasi, Joseph A; Smith, Zachary; Getz, Kenneth A.

Afiliación

DiMasi JA; Tufts Center for the Study of Drug Development, Tufts University, Boston, Massachusetts. Electronic address: joseph.dimasi@tufts.edu.
Smith Z; Tufts Center for the Study of Drug Development, Tufts University, Boston, Massachusetts.
Getz KA; Tufts Center for the Study of Drug Development, Tufts University, Boston, Massachusetts.

Clin Ther ; 40(6): 963-972, 2018 06.

Article en En | MEDLINE | ID: mdl-29755005

Asunto(s)

Desarrollo de Medicamentos/economía; Servicios Externos/economía; Comercio; Costos y Análisis de Costo; Industria Farmacéutica

Palabras clave

biopharmaceutical R&D cost; biopharmaceutical net returns; contract manufacturing; drug development time

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Servicios Externos / Desarrollo de Medicamentos Tipo de estudio: Health_economic_evaluation / Prognostic_studies Idioma: En Revista: Clin Ther Año: 2018 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google